FGFR1 and lymphoid neoplasm: In August 2022, the US FDA approved pemigatinib for treatment of relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement, based on the results of phase 2-FIGHT-203 Study (NCT03011372) that show a complete response of 75.8% in previously treated patients [22].